Abstract
Most depressed patients suffer from sleep abnormalities, which are one of the critical symptoms of depression. They are robust risk factors for the initiation and development of depression. Studies about sleep electroencephalograms have shown characteristic changes in depression such as reductions in non-rapid eye movement sleep production, disruptions of sleep continuity and disinhibition of rapid eye movement (REM) sleep. REM sleep alterations include a decrease in REM sleep latency, an increase in REM sleep duration and REM sleep density with respect to depressive episodes. Emotional brain processing dependent on the normal sleep-wake regulation seems to be failed in depression, which also promotes the development of clinical depression. Also, REM sleep alterations have been considered as biomarkers of depression. The disturbances of norepinephrine and serotonin systems may contribute to REM sleep abnormalities in depression. Lastly, this review also discusses the effects of different antidepressants on REM sleep disturbances in depression.
Keywords: Antidepressants, depression, mood disorders, norepinephrine, serotonin, sleep disorders.
Graphical Abstract
Current Neuropharmacology
Title:The Neurobiological Mechanisms and Treatments of REM Sleep Disturbances in Depression
Volume: 13 Issue: 4
Author(s): Yi-Qun Wang, Rui Li, Meng-Qi Zhang, Ze Zhang, Wei-Min Qu and Zhi-Li Huang
Affiliation:
Keywords: Antidepressants, depression, mood disorders, norepinephrine, serotonin, sleep disorders.
Abstract: Most depressed patients suffer from sleep abnormalities, which are one of the critical symptoms of depression. They are robust risk factors for the initiation and development of depression. Studies about sleep electroencephalograms have shown characteristic changes in depression such as reductions in non-rapid eye movement sleep production, disruptions of sleep continuity and disinhibition of rapid eye movement (REM) sleep. REM sleep alterations include a decrease in REM sleep latency, an increase in REM sleep duration and REM sleep density with respect to depressive episodes. Emotional brain processing dependent on the normal sleep-wake regulation seems to be failed in depression, which also promotes the development of clinical depression. Also, REM sleep alterations have been considered as biomarkers of depression. The disturbances of norepinephrine and serotonin systems may contribute to REM sleep abnormalities in depression. Lastly, this review also discusses the effects of different antidepressants on REM sleep disturbances in depression.
Export Options
About this article
Cite this article as:
Wang Yi-Qun, Li Rui, Zhang Meng-Qi, Zhang Ze, Qu Wei-Min and Huang Zhi-Li, The Neurobiological Mechanisms and Treatments of REM Sleep Disturbances in Depression, Current Neuropharmacology 2015; 13 (4) . https://dx.doi.org/10.2174/1570159X13666150310002540
DOI https://dx.doi.org/10.2174/1570159X13666150310002540 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Neuroinflammation, Microglia and Mast Cells in the Pathophysiology of Neurocognitive Disorders: A Review
CNS & Neurological Disorders - Drug Targets Inflammation in Parkinsons Diseases and Other Neurodegenerative Diseases: Cause and Therapeutic Implications
Current Pharmaceutical Design Targeting TNF-Alpha to Elucidate and Ameliorate Neuroinflammation in Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Ubiquitin-Proteasome Pathway Components as Therapeutic Targets for CNS Maladies
Current Pharmaceutical Design Endothelins and the Role of Endothelin Antagonists in the Management of Posttraumatic Vasospasm
Current Pharmaceutical Design Therapeutic Approach for Neuronal Disease by Regulating Reninangiotensin System
Current Hypertension Reviews A Synthesis of Functional Neuroimaging in the Frontal Variant of Frontotemporal Dementia
Current Medical Imaging Do Geriatric Outpatients Adhere to Medication Changes Advised After Assessment? An Exploratory Pilot Study
Current Clinical Pharmacology N-Phenylamine Derivatives as Aggregation Inhibitors in Cell Models of Tauopathy
Current Alzheimer Research Evolution of Novel Non-Steroidal Anti-Inflammatory Drugs with Reduced Gastrointestinal Adverse Effects
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Computer based Classification of MR Scans in First Time Applicant Alzheimer Patients
Current Alzheimer Research Diabetes Mellitus to Neurodegenerative Disorders: Is Oxidative Stress Fueling the Flame?
CNS & Neurological Disorders - Drug Targets ABAD: A Potential Therapeutic Target for Aβ-Induced Mitochondrial Dysfunction in Alzheimers Disease
Mini-Reviews in Medicinal Chemistry Benzothiazoles - Scaffold of Interest for CNS Targeted Drugs
Current Medicinal Chemistry Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction
Current Pharmaceutical Design Neuropharmacology of the Endocannabinoid Signaling System-Molecular Mechanisms, Biological Actions and Synaptic Plasticity
Current Neuropharmacology Understanding the Potential Role and Delivery Approaches of Nitric Oxide in Chronic Wound Healing Management
Current Pharmaceutical Design Acute Symptomatic Seizures in Geriatric Patients with Multiple Risk Factors - A Diagnostic Challenge
Current Aging Science Molecular Mechanisms of Ischemic Neuronal Cell Death - With Relevance to Alzheimers Disease
Current Alzheimer Research Disease-Modifying Therapies in Frontotemporal Lobar Degeneration
Current Medicinal Chemistry